Petros Pharma Files S-1/A Amendment

TL;DR

Petros Pharma updated its S-1/A filing on Feb 10, 2025. Financials show $2.99M current assets vs $2.08M current liabilities as of 12/31/23.

AI Summary

Petros Pharmaceuticals, Inc. filed an S-1/A amendment on February 10, 2025, related to its 1933 Act registration. The filing includes financial data points such as $2,991,377 in current assets and $2,079,387 in current liabilities as of December 31, 2023. It also references fair value adjustments for warrants and various measurement inputs like risk-free interest rates and price volatility.

Why It Matters

This S-1/A filing provides updated financial disclosures and registration details for Petros Pharmaceuticals, which is crucial for investors to assess the company's current financial health and regulatory standing.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carries risk for investors.

Key Numbers

• $2.99B — Current Assets (As of December 31, 2023, indicating short-term financial resources.)
• $2.08B — Current Liabilities (As of December 31, 2023, representing short-term obligations.)
• 20250210 — Filing Date (The date the S-1/A amendment was submitted to the SEC.)

Key Players & Entities

• Petros Pharmaceuticals, Inc. (company) — Filer of the S-1/A amendment
• February 10, 2025 (date) — Filing date of the S-1/A amendment
• 1933 Act (legal_document) — Securities Act under which the registration is filed
• $2,991,377 (dollar_amount) — Current assets as of December 31, 2023
• $2,079,387 (dollar_amount) — Current liabilities as of December 31, 2023
• December 31, 2023 (date) — Fiscal year-end for financial data presented

FAQ

Key Financial Figures

• $0.0001 — sting of one share of our common stock, $0.0001 par value per share ("common stock"), a
• $0.269 — at the assumed public offering price of $0.269 per Unit, which was the last reported s
• $0.2576 — stock on The Nasdaq Capital Market was $0.2576 per share. We are an "emerging growth
• $125,000 — t-of-pocket expenses in an amount up to $125,000. See " Plan of Distribution " for a des

Filing Documents

• tmb-20240930xs1a.htm (S-1/A) — 4861KB
• tmb-20240930xex4d7.htm (EX-4.7) — 177KB
• tmb-20240930xex4d8.htm (EX-4.8) — 166KB
• tmb-20240930xex4d9.htm (EX-4.9) — 120KB
• tmb-20240930xex5d1.htm (EX-5.1) — 23KB
• tmb-20240930xex10d20.htm (EX-10.20) — 239KB
• tmb-20240930xex10d22.htm (EX-10.22) — 22KB
• tmb-20240930xex10d23.htm (EX-10.23) — 13KB
• tmb-20240930xex23d1.htm (EX-23.1) — 3KB
• tmb-20240930xex23d2.htm (EX-23.2) — 2KB
• tmb-20240930xexfees.htm (EX-FILING FEES) — 96KB
• tmb-20240930xs1a002.jpg (GRAPHIC) — 12KB
• 0001410578-25-000108.txt ( ) — 21206KB
• tmb-20240930.xsd (EX-101.SCH) — 125KB
• tmb-20240930_cal.xml (EX-101.CAL) — 77KB
• tmb-20240930_def.xml (EX-101.DEF) — 499KB
• tmb-20240930_lab.xml (EX-101.LAB) — 782KB
• tmb-20240930_pre.xml (EX-101.PRE) — 960KB
• tmb-20240930xs1a_htm.xml (XML) — 3048KB

USE OF PROCEEDS

USE OF PROCEEDS 41 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 42 CAPITALIZATION 43

DILUTION

DILUTION 45 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 47

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 50

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 56 MATERIAL US FEDERAL INCOME TAX CONSEQUENCES 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 69 PLAN OF DISTRIBUTION 70

MANAGEMENTS DISCUSSION AND ANALYSIS

MANAGEMENTS DISCUSSION AND ANALYSIS 77 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 100 EXECUTIVE AND DIRECTOR COMPENSATION 107 PRINCIPAL STOCKHOLDERS 111 EXPERTS 114 LEGAL MATTERS 114 WHERE YOU CAN FIND MORE INFORMATION 114

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS The registration statement on Form S-1, which we filed with the Securities and Exchange Commission (the "SEC") and of which this prospectus forms a part, includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision. You should rely only on the information provided in this prospectus. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find Additional Information." We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no a

View Full Filing

View this S-1/A filing on SEC EDGAR